Holen Sie sich die Stockscreener-App
10.82
3.29%
0.34
Handel nachbörslich:
10.82
Schlusskurs vom Vortag:
$10.48
Offen:
$10.35
24-Stunden-Volumen:
112.27K
Relative Volume:
0.62
Marktkapitalisierung:
$357.94M
Einnahmen:
$65.42M
Nettoeinkommen (Verlust:
$-32.96M
KGV:
-8.5197
EPS:
-1.27
Netto-Cashflow:
$-19.87M
1W Leistung:
+1.64%
1M Leistung:
+9.79%
6M Leistung:
+1.45%
1J Leistung:
+67.57%
1-Tages-Spanne:
$10.15
$10.85
1-Wochen-Bereich:
$10.15
$11.25
52-Wochen-Spanne:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Firmenname
Neuropace Inc
Sektor
Branche
Telefon
(650) 237-2700
Adresse
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Vergleichen Sie NPCE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
10.82 | 340.08M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
133.26 | 228.66B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
96.24 | 140.69B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.88 | 139.51B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
96.53 | 122.60B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.35 | 42.83B | 5.69B | 1.41B | 577.90M | 6.9828 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-21 | Eingeleitet | UBS | Buy |
| 2024-03-14 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | Eingeleitet | Lake Street | Buy |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-05-17 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-17 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Neuropace Inc Aktie (NPCE) Neueste Nachrichten
NeuroPace Inc. stock outlook for YEARJuly 2025 PreEarnings & Verified Swing Trading Watchlists - newser.com
Applying Elliott Wave Theory to NeuroPace Inc.July 2025 Breakouts & Real-Time Market Trend Scan - newser.com
Can NeuroPace Inc. rally from current levels2025 AllTime Highs & Verified Momentum Stock Alerts - newser.com
Can NeuroPace Inc. stock sustain revenue growthTreasury Yields & Community Verified Trade Alerts - newser.com
Tools to assess NeuroPace Inc.’s risk profileJuly 2025 Price Swings & Capital Efficiency Focused Strategies - newser.com
How to integrate NeuroPace Inc. into portfolio analysis toolsJuly 2025 Market Mood & Verified Technical Trade Signals - newser.com
Will NeuroPace Inc. price bounce be sustainableJuly 2025 Movers & Safe Entry Point Identification - newser.com
NeuroPace, Inc. (NASDAQ:NPCE) Receives $16.60 Average Price Target from Analysts - Defense World
NeuroPace's (NPCE) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Automated trading signals detected on NeuroPace Inc.Trade Analysis Summary & Free Technical Pattern Based Buy Signals - newser.com
What momentum shifts mean for NeuroPace Inc.2025 Market Overview & Community Consensus Stock Picks - newser.com
NeuroPace Inc. recovery potential after sell offInsider Selling & Verified Swing Trading Watchlist - newser.com
What analysts say about NeuroPace Inc stockEx-Dividend Date Alerts & Stay One Step Ahead of Risk Events - earlytimes.in
NeuroPace, Inc. (NASDAQ:NPCE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
NeuroPace Inc Stock Analysis and ForecastDouble Top/Bottom Patterns & Affordable Portfolio Growth - earlytimes.in
Using economic indicators to assess NeuroPace Inc. potentialJuly 2025 Setups & AI Powered Market Entry Ideas - newser.com
HighMark Wealth Management LLC Purchases 60,000 Shares of NeuroPace, Inc. $NPCE - MarketBeat
Neuropace chief medical officer Morrell sells $48,032 in stock - MSN
What drives NeuroPace Inc stock priceTrading Volume Surges & Get Mentorship from Elite Traders - earlytimes.in
Epilepsy Treatment Devices Market Hits New High | Medtronic, NeuroPace, LivaNova, Boston Scientific - newstrail.com
Why NeuroPace Inc. stock is trending among retail tradersJuly 2025 Final Week & Growth Focused Stock Pick Reports - The British Mountaineering Council
Palumbo Wealth Management LLC Grows Stake in NeuroPace, Inc. $NPCE - MarketBeat
Why NeuroPace Inc. is moving todayGap Down & Comprehensive Market Scan Reports - newser.com
Will NeuroPace Inc. outperform the marketWeekly Profit Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Is NeuroPace Inc. building a consolidation baseInsider Selling & Short-Term Swing Trade Alerts - newser.com
NeuroPace Inc. stock prediction for this weekPortfolio Gains Report & Safe Entry Zone Identification - newser.com
Forecasting NeuroPace Inc. price range with options data2025 Short Interest & Target Return Focused Stock Picks - newser.com
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 25% Price Jump - simplywall.st
Using Vision Transformers for Electrographic Seizure Classification to Aid Physician Review of Intracranial Electroencephalography Recordings - Frontiers
Using vision transformers for electrographic seizure classification to aid physician review of intracranial electroencephalography recordings - Frontiers
How to recover losses in NeuroPace Inc. stock2025 Top Decliners & Short-Term Swing Trade Alerts - newser.com
Finanzdaten der Neuropace Inc-Aktie (NPCE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neuropace Inc-Aktie (NPCE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
1.22%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):